The UK and US have finalized a landmark bilateral deal that will preserve zero import taxes on UK pharmaceutical products being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to raise spending on drugs through the NHS. This commitment ensures that duties on these key goods will stay at zero for a period of the next three years.
This development follows previous threats to significantly raise tariffs on patented drug products, with potential rates mentioned reaching 100%.
"This deal between the Britain reinforces the international landscape for cutting-edge drugs and brings much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement declared.
Trade Significance
Pharmaceuticals are one of the UK's most significant exports to the America, which is by far the biggest buyer for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to the third quarter, the UK sold medicines valued at over eleven billion pounds to the US. This figure accounted for nearly one-fifth of British export trade in that period.
"This guarantee safeguards jobs, boosts funding and paves the way for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary stated.
Detailed UK Commitments
The agreement includes several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to double overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. Previously, rebates topped 20%.
Recent Tensions
The deal comes amid a protracted dispute between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
These tensions were exacerbated by claims that American patients were charged a premium for the identical medicines than people in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar investments have been directed toward projects in the United States.
One official publicly accepted that the NHS had to spend more on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the past decade.
